Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

KS Biomedix's KSB-301 enters phase II for osteoarthritis

Feb. 12, 2001

NCX-530 is less toxic than indomethacin to the intestine according to rat studies

Feb. 12, 2001

SCIO-469 now being studied in phase Ib trial for treatment of RA

Feb. 9, 2001

Combinations of etanercept and a COX-2 inhibitor claimed by Pharmacia for Rx of inflammation

Feb. 7, 2001

Pyrazole-based inhibitors of p38 MAP kinase identified at Teikoku Hormone

Feb. 6, 2001

E.U. approves Remicade for broader RA indication

Feb. 6, 2001

Overseas development of TR-14035 to be managed by GlaxoSmithKline

Feb. 5, 2001

New MMP-inhibitory hydroxamic acid derivatives and use thereof

Feb. 2, 2001

Dimethaid begins mutual recognition procedure in E.U. for Pennsaid

Feb. 2, 2001

Patent assigned to Warner-Lambert covers MMP inhibitors for various disorders

Feb. 1, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
$Silhouette of head and brainwith fractal art$
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit
BioWorld
Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...